TherapeuticsMD (TXMD) reported second-quarter 2026 net income from continuing operations of $164,000, compared with $545,000 in the second quarter of 2025. License revenue was $869,000, compared with $952,000 a year earlier.
The company said operating expenses from continuing operations were $1.7 million and cash and cash equivalents totaled $9.2 million as of June 30, 2026. TherapeuticsMD said it continues to evaluate strategic alternatives, including a possible acquisition, merger, business combination, asset sale or other strategic transaction.
- Second-quarter 2026 license revenue was $869,000, down from $952,000 in the prior-year quarter.
- Net income from continuing operations was $164,000, compared with $545,000 a year earlier.
- Total operating expenses from continuing operations were $1.7 million, up $38,000, or 2.3%, from the second quarter of 2025.
- Cash and cash equivalents totaled $9.2 million as of June 30, 2026.
- The company said it is no longer engaged in research and development or commercial operations and primarily collects royalties from licensees.
$TXMD Hedge Fund Activity
We have seen 14 institutional investors add shares of $TXMD stock to their portfolio, and 12 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SQUADRON CAPITAL MANAGEMENT LLC added 420,421 shares (+inf%) to their portfolio in Q1 2026, for an estimated $849,250
- RENAISSANCE TECHNOLOGIES LLC added 49,700 shares (+51.5%) to their portfolio in Q1 2026, for an estimated $100,394
- CITADEL ADVISORS LLC added 40,074 shares (+141.9%) to their portfolio in Q1 2026, for an estimated $80,949
- XTX TOPCO LTD added 27,487 shares (+inf%) to their portfolio in Q1 2026, for an estimated $55,523
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 13,944 shares (-39.7%) from their portfolio in Q1 2026, for an estimated $28,166
- OSAIC HOLDINGS, INC. removed 9,144 shares (-98.4%) from their portfolio in Q1 2026, for an estimated $18,470
- CYGNUS CAPITAL ADVISORS, LLC added 9,069 shares (+inf%) to their portfolio in Q1 2026, for an estimated $18,319
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
